Being Alive; February 1994
Henry E. Chang
The three year grant will fund three interdependent projects focused on an antiviral technology called "capsid targeted viral inactivation" (CTVI). The technology involves creating a hybrid gene that, when transferred into HIV-infected cells, targets and destroys the virus as it replicates. This then decreases the overall viral burden. The principal goal of the project is to study the role that accessory virus proteins, known as Vpx and Vpr, play in the life cycle of HIV.
Avigen scientists will use adeno-associated virus (AAV) vectors to deliver CTVI gene constructs to cells in culture to test for anti-HIV activity. The lab findings will be used to support eventual primate studies and human clinical trials.
940201
BA940208
Copyright © 1994 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/